newsfilter
← Latest News
GlobeNewswire·

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to